Filters
New Court, new approaches: How the UPC is reshaping pharmaceutical patent litigation
The German Government’s Grid Package: New Rules for Grid Connection
The in-house exception in 2026: the turnover of the entire group may be relevant for the activity criterion
#7: State of the EU Crypto Industry: MiCA, Tokenisation and What Comes Next
The justified unequal treatment of economic operators from third countries
The primary subject matter of the contract is decisive in determining whether a procurement procedure must be followed
The often-overlooked requirement to specify the maximum value
Vendor lock-in is no carte blanche for a direct award
Proposed Amendments to the EU Medical Device Regulation
A European Perspective #1 | The Commission’s proposed MDR/IVDR reform introduces substantial changes to certification, classification and compliance frameworks. Medical device companies should assess potential im-pacts early and prepare for a shifting regulatory landscape.
2 of 9 Insights
Impact of the new Biotech Act on Clinical Trials in the EU
A European Perspective #1 | EU Biotech Act: Faster Clinical Trial Approvals Ahead | The European Commission’s proposed Biotech Act aims to streamline clinical trial procedures, shorten approval timelines, and harmonise data protection rules across the EU. If adopted, the reform could significantly accelerate multinational clinical research in the EU.
4 of 9 Insights
The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU
A European Perspective #1 | The EU’s largest pharmaceutical law reform in over 20 years introduces a new regulatory exclusivity framework, revised orphan drug incentives and an antimicrobial voucher. Strategic exclusivity planning will become essential for pharmaceutical companies.
1 of 9 Insights
Employer agreements on employees and the cartel prohibition